The Ohio State University

Ohio State Innovation Foundation

National Taiwan University

Taipei Medical University

Other

Ching-Shih Chen

Dasheng Wang

Samuel K Kulp

Hao-Chieh Chiu

Larry Schlesinger

John C Byrd

Natarajan Muthusamy

Tanios Bekaii-Saab

John S Gunn

Jing-Ru Weng

Yu-Chou Tseng

Che-Ming Teng

Jing-Ping Liou

Wen-Ta Chiu

Guido Marcucci

Kuo-Sheng Hung

Danilo Perrotti

Pei-Wen Shan

Chung-Wai Shiau

Christopher C Coss

Hsing-Jin Liu

James T Dalton

Jih-Hwa Guh

Jian Yang

Paolo Neviani

Abul K Azad

Denis Guttridge

Arthur Y Shaw

Yeng-Jeng Shaw

Santosh Salunke

Jason B Garrison

Natasha Kyprianou

Frank Frissora

Xiaobin Zhao

Qing Liu

Xueqin Song

Matthew David Ringel

Ho-Pi Lin

Motoyashi Saji

Yihui Ma

Su-Lin Lee

Ramasamy Santhanam

Yu-Wei Leu

Shu-Huei Hsiao

Lu Qiang

Larry Seth Schlesinger Schlesinger

John Spencer Gunn Gunn

Jian Wang

In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

Methods and compositions for the treatment of cancer cachexia

Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.

Methods for suppressing cancer-related cachexia

Indolyl or indolinyl compounds of formula (I): whereinbond, n, R, R, R, R, R, and R, are defined herein. Also disclosed is a method for treating cancer with these compounds.

Indolyl or indolinyl hydroxamate compounds

Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as

Antibacterial protein kinase inhibitors

Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.

Glucose transporter inhibitors

Compounds according to formula I: wherein Ar is a fused aryl group, Ris selected from alkyl and aryl amides, CF, and CHOH, and Ris selected from hydrogen, &#x2014;C(&#x2550;O)CHNH, and &#x2014;C(&#x2550;O)CHCHNHare described. The compounds are effective for inhibiting p21-activated kinases, and can be used for prevention and treatment of cancer.

Anticancer P21-activated kinase inhibitors

Zn-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.

[object Object]

A method of treating infection byin a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described.The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.

Anti-staphylococcal celecoxib derivatives

A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is &#x2014;CF, Ar is selected from and R is selected from  

Anti-infective agents against intracellular pathogens

Compounds and methods for treating cancer or inducing apoptosis in proliferating cells. The compounds are shown in formula I: wherein X is selected from hydroxyl, thiol, and amino; Y is selected from carboxyl and sulfonyl; R, R, R, and Rare selected from hydrogen, lower alkyl, and combinations thereof; R, R, and Rare selected from hydrogen, halo, ni tro, amino, methoxy, and combinations thereof; and pharmaceutically acceptable salts thereof.

Alkyl indole-3-carbinol-derived antitumor agents

A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.

Integrin-linked kinase inhibitors

The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph'-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.

Therapeutic agents for the treatment of leukemia

A series of celecoxib derivatives defined by Formula I: were prepared and evaluated for their ability to inhibit the gram-negative bacteria. Pharmaceutical compositions including celecoxib derivatives and their use in methods for treating or preventing infection byin a subject are described.

Growing community of inventors

Upper Arlington, OH, United States of America

Ching-Shih Chen